A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00578786 |
|
Recruitment Status :
Completed
First Posted : December 21, 2007
Results First Posted : January 15, 2013
Last Update Posted : January 15, 2013
|
Sponsor:
Gilead Sciences
Information provided by (Responsible Party):
Gilead Sciences
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
AMB-320/321-E was designed to provide long-term, controlled monitoring of pulmonary arterial hypertension (PAH) patients treated with ambrisentan (AMB) in order to properly define the adverse event profile associated with this endothelin receptor antagonist (ERA), including the incidence and severity of elevated serum liver function tests (LFTs). In addition, this study continued the efficacy assessments of the previous studies, examined long-term AMB treatment success, and compared long-term survival of subjects treated with AMB to the NIH registry of patients with PAH.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Pulmonary Arterial Hypertension | Drug: ambrisentan | Phase 3 |
AMB-320 (ARIES-1; NCT00423748) and AMB-321 (ARIES-2; NCT00423202) were 12-week, Phase 3, randomized, double-blind, placebo-controlled, multicenter, efficacy studies of AMB in subjects with PAH. The objectives of these studies were to determine the effect of three doses of AMB (2.5, 5.0, and 10.0 mg) on exercise capacity, as well as several clinical measures of PAH. The current study (NCT00578786) was unblinded (by design) prior to completion. The ARIES studies were identical except for the dose groups assessed and the geographic locations where the studies were conducted. Both studies evaluated placebo and 5.0-mg AMB dose groups; however, AMB-320 (NCT00423748) also examined an AMB dose of 10.0 mg, while AMB-321 (NCT00423202) included an AMB dose of 2.5 mg. AMB-320/321-E was an optional study for subjects who had participated in AMB-320 (NCT00423748) or AMB-321 (NCT00423202) that allowed continued long-term treatment with AMB.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 383 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) |
| Study Start Date : | February 2004 |
| Actual Primary Completion Date : | March 2010 |
| Actual Study Completion Date : | March 2010 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Ambrisentan
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Ambrisentan
2.5, 5 or 10 mg ambrisentan
|
Drug: ambrisentan
2.5, 5.0 or 10.0 mg ambrisentan po, qd, long-term
Other Name: Letairis(TM) |
Primary Outcome Measures :
- Frequently Reported (15% or More Overall) Adverse Events by Severity [ Time Frame: Baseline to Week 295 ]The primary endpoint of this study is the incidence and severity of adverse events associated with long-term exposure to AMB in participants with PAH. The most frequently occurring adverse events (occurring in 15% or more of the participants in the combined group) are presented, by severity, that began after entering this extension study. Adverse events that were serious are included. Adverse events are coded according to the Medical Dictionary for Regulatory Activities (MedDRA) Version 6.1 and are presented by MedDRA preferred term. Severity was graded as follows: mild (AE did not interfere with routine activities; subject may have experienced slight discomfort), moderate (AE interfered with routine activities; subject may have experienced significant discomfort), and severe (AE made it impossible to perform routine activities; subject may have experienced intolerable discomfort or pain).
- Serum Aminotransferases Relative to the Upper Limit of the Normal Range (ULN) [ Time Frame: Baseline to Week 295 ]The number of participants with serum alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST) falling into the following categories: >3.0 and </= 5.0 x ULN, >5.0 and </= 8.0 x ULN, and >8.0 x ULN. Includes the highest value per participant across all visits as well as values from early termination visits.
Secondary Outcome Measures :
- Baseline Exercise Capacity as Measured by the 6-Minute Walk Distance Test [ Time Frame: Baseline ]The 6-minute walk distance (6MWD) test was conducted according to the American Thoracic Society guidelines (ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166(1):111-117.).
- Change From Baseline to Week 24 in Exercise Capacity as Measured by the 6-Minute Walk Distance Test [ Time Frame: Baseline to Week 24 ]The 6-minute walk distance (6MWD) test was conducted according to the American Thoracic Society guidelines (ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166(1):111-117.). Missing values were imputed using LOCF method based on post-baseline observations. Baseline (BL) values from the screening/randomization visit of the 2 prior studies defined the BL of this long-term analysis for those receiving ambrisentan in the prior studies. The Screening/Randomization Visit of the present study was the BL for subjects receiving placebo in the prior studies.
- Change From Baseline to Week 48 (Year 1) in Exercise Capacity as Measured by the 6-Minute Walk Distance Test [ Time Frame: Baseline to Week 48 ]The 6-minute walk distance (6MWD) test was conducted according to the American Thoracic Society guidelines (ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166(1):111-117.). The last-observation-carried-forward (LOCF) imputation method was used. Baseline (BL) values from the screening/randomization visit of the 2 prior studies defined the BL of this long-term analysis for those receiving AMB in the prior studies. The Screening/Randomization Visit of the present study was the BL for subjects receiving placebo in the prior studies.
- Change From Baseline to Year 2 in Exercise Capacity as Measured by the 6-Minute Walk Distance Test [ Time Frame: Baseline to Year 2 ]The 6-minute walk distance (6MWD) test was conducted according to the American Thoracic Society guidelines (ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166(1):111-117.). The last-observation-carried-forward (LOCF) imputation method was used. Baseline (BL) values from the screening/randomization visit of the 2 prior studies defined the BL of this long-term analysis for those receiving AMB in the prior studies. The Screening/Randomization Visit of the present study was the BL for subjects receiving placebo in the prior studies.
- Change From Baseline to Year 3 in Exercise Capacity as Measured by the 6-Minute Walk Distance Test [ Time Frame: Baseline to Year 3 ]Thoracic Society guidelines (ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166(1):111-117.). The last-observation-carried-forward (LOCF) imputation method was used. Baseline (BL) values from the screening/randomization visit of the 2 prior studies defined the BL of this long-term analysis for those receiving AMB in the prior studies. The Screening/Randomization Visit of the present study was the BL for subjects receiving placebo in the prior studies.
- Baseline Borg Dyspnea Index [ Time Frame: Baseline ]Borg Dyspnea Index is a measure of perceived shortness of breath: 0 units on a scale (none) to 10 units on a scale (maximum breathlessness).
- Change From Baseline to Year 1 in Borg Dyspnea Index [ Time Frame: Baseline to Year 1 ]Borg Dyspnea Index is a measure of perceived shortness of breath: 0 units on a scale (none) to 10 units on a scale (maximum breathlessness). Baseline (BL) values from the screening/randomization visit of the 2 prior studies defined the BL of this long-term analysis for those receiving ambrisentan in the prior studies. The Screening/Randomization Visit of the present study was the BL for subjects receiving placebo in the prior studies.
- Change From Baseline to Year 2 in Borg Dyspnea Index [ Time Frame: Baseline to Year 2 ]Borg Dyspnea Index is a measure of perceived shortness of breath: 0 units on a scale (none) to 10 units on a scale (maximum breathlessness). Baseline (BL) values from the screening/randomization visit of the 2 prior studies defined the BL of this long-term analysis for those receiving AMB in the prior studies. The Screening/Randomization Visit of the present study was the BL for subjects receiving placebo in the prior studies.
- Change From Baseline to Year 3 in Borg Dyspnea Index [ Time Frame: Baseline to Year 3 ]Borg Dyspnea Index is a measure of perceived shortness of breath: 0 units on a scale (none) to 10 units on a scale (maximum breathlessness). Baseline (BL) values from the screening/randomization visit of the 2 prior studies defined the BL of this long-term analysis for those receiving AMB in the prior studies. The Screening/Randomization Visit of the present study was the BL for subjects receiving placebo in the prior studies.
- Baseline World Health Organization (WHO) Functional Class [ Time Frame: Baseline ]WHO Classes: I) pulmonary hypertension (PH); ordinary physical activity not limited or causes increased dyspnea, fatigue, chest pain, or presyncope. II) PH; ordinary physical activity mildly limited and causes increased dyspnea, fatigue, chest pain, or presyncope; comfortable at rest. III) PH; physical activity markedly limited and less than ordinary physical activity causes increased dyspnea, fatigue, chest pain, or presyncope; comfortable at rest. IV) PH; physical activity causes symptoms; signs of right heart failure; dyspnea/fatigue possible at rest.
- Change From Baseline to Year 1 in World Health Organization (WHO) Functional Class [ Time Frame: Baseline to Year 1 ]WHO Classes: I) pulmonary hypertension (PH); ordinary physical activity not limited or causes increased dyspnea, fatigue, chest pain, or presyncope. II) PH; ordinary physical activity mildly limited and causes increased dyspnea, fatigue, chest pain, or presyncope; comfortable at rest. III) PH; physical activity markedly limited and less than ordinary physical activity causes increased dyspnea, fatigue, chest pain, or presyncope; comfortable at rest. IV) PH; physical activity causes symptoms; signs of right heart failure; dyspnea/fatigue possible at rest.
- Change From Baseline to Year 2 in World Health Organization (WHO) Functional Class [ Time Frame: Baseline to Year 2 ]WHO Classes: I) pulmonary hypertension (PH); ordinary physical activity not limited or causes increased dyspnea, fatigue, chest pain, or presyncope. II) PH; ordinary physical activity mildly limited and causes increased dyspnea, fatigue, chest pain, or presyncope; comfortable at rest. III) PH; physical activity markedly limited and less than ordinary physical activity causes increased dyspnea, fatigue, chest pain, or presyncope; comfortable at rest. IV) PH; physical activity causes symptoms; signs of right heart failure; dyspnea/fatigue possible at rest.
- Change From Baseline to Year 3 in World Health Organization (WHO) Functional Class [ Time Frame: Baseline to Year 3 ]WHO Classes: I) pulmonary hypertension (PH); ordinary physical activity not limited or causes increased dyspnea, fatigue, chest pain, or presyncope. II) PH; ordinary physical activity mildly limited and causes increased dyspnea, fatigue, chest pain, or presyncope; comfortable at rest. III) PH; physical activity markedly limited and less than ordinary physical activity causes increased dyspnea, fatigue, chest pain, or presyncope; comfortable at rest. IV) PH; physical activity causes symptoms; signs of right heart failure; dyspnea/fatigue possible at rest.
- Baseline SF-36 Health Survey Scales for the Combined Ambrisentan Group [ Time Frame: Baseline ]The 8 scales of the SF-36 Health Survey measured included physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health, and the summary measures included physical health and mental health. Scores for each scale are transformed and the transformed scores range from 0 (worst health) to 100 (best health). The scores are then standardized with the 1998 General United States (US) population mean and standard deviation (SD). Finally, the scores are transformed to the norm-based scoring with a mean of 50 and SD of 10.
- Change From Baseline to Week 12 in SF-36 Health Survey Scales for the Combined Ambrisentan Group [ Time Frame: Baseline to Week 12 ]The 8 scales of the SF-36 Health Survey measured included physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health, and the summary measures included physical health and mental health. Scores for each scale are transformed and the transformed scores range from 0 (worst health) to 100 (best health). The scores are then standardized with the 1998 General US population mean and SD. Finally, the scores are transformed to the norm-based scoring with a mean of 50 and SD of 10.
- Change From Baseline to Week 24 in SF-36 Health Survey Scales for the Combined Ambrisentan Group [ Time Frame: Baseline to Week 24 ]The 8 scales of the SF-36 Health Survey measured included physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health, and the summary measures included physical health and mental health. Scores for each scale are transformed and the transformed scores range from 0 (worst health) to 100 (best health). The scores are then standardized with the 1998 General US population mean and SD. Finally, the scores are transformed to the norm-based scoring with a mean of 50 and SD of 10.
- Change From Baseline to Week 36 in SF-36 Health Survey Scales for the Combined Ambrisentan Group [ Time Frame: Baseline to Week 36 ]The 8 scales of the SF-36 Health Survey measured included physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health, and the summary measures included physical health and mental health. Scores for each scale are transformed and the transformed scores range from 0 (worst health) to 100 (best health). The scores are then standardized with the 1998 General US population mean and SD. Finally, the scores are transformed to the norm-based scoring with a mean of 50 and SD of 10.
- Percentage of Participants With No Clinical Worsening of PAH [ Time Frame: Baseline to Year 3 ]Clinical worsening of PAH was defined as the time from randomization to ambrisentan therapy to the first occurrence of death, lung transplantation, hospitalization for PAH, atrial septostomy, addition of approved prostanoid therapy, study withdrawal due to the addition of other clinically approved PAH therapeutics, or study withdrawal due to 2 or more early escape criteria (for subjects randomized to AMB in NCT00423748 or NCT00423202). Results are presented as the Kaplan-Meier estimate (% probability) of not having clinical worsening after a given time.
- Percentage of Participants With Failure-Free Treatment Status [ Time Frame: Baseline to Year 4 ]Treatment failure was defined as the time from randomization to ambrisentan therapy to the first occurrence of death, lung transplantation, addition of approved prostanoid therapy, study withdrawal due to the addition of other clinically approved PAH therapeutics, or study withdrawal due to 2 or more early escape criteria (for subjects randomized to ambrisentan in NCT00423748 or NCT00423202). Results are presented as the Kaplan-Meier estimate (% probability) of not having treatment failure after a given time.
- Long-term Survival [ Time Frame: Baseline to Year 4 ]Long-term survival was defined as the time from initiation of active treatment to death. Results are presented as the Kaplan-Meier estimate (% probability) of survival after a given time.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subject must have completed Week 12 of AMB-320 (NCT00423748) or AMB-321 (NCT00423202) or must have received placebo during AMB-320 (NCT00423748) or AMB-321 (NCT00423202) and met two or more early escape criteria;
- Subject must be competent to understand the information given in the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved informed consent form and must sign the form prior to the initiation of any study procedures.
- Female subject of childbearing potential must agree to use two reliable methods of contraception until study completion and for at least four weeks following their final study visit. Reliable methods include: birth control pills/implants/injections, intrauterine devices (IUDs), spermicide, diaphragms, or condoms.
Exclusion Criteria:
-
Subjects must have met the exclusion criteria of the AMB-320 (NCT00423748) and AMB-321 (NCT00423202)studies. In addition, a subject who meets any one of the following criteria is ineligible for participation in the study:
- Subject receiving bosentan, sildenafil, or iv inotropes at any time within four weeks prior to the AMB-320/321-E Screening/Randomization Visit;
- Subject receiving chronic prostanoid therapy (epoprostenol, treprostinil, iloprost, beraprost, or any other investigational prostacyclin derivative) within four weeks prior to the AMB-320/321-E Screening/RandomizationVisit;
- Female subject who is pregnant or breastfeeding;
- Subject with cardiovascular, liver, renal, hematologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease that, in the opinion of the Investigator, may adversely affect the safety of the subject and/or efficacy of the study drug or severely limit the lifespan of the subject;
- Subject who has demonstrated noncompliance with previous medical regimens;
- Subject who has a recent history of abusing alcohol or illicit drugs;
- Subject who has participated in a clinical study involving another investigational drug or device at any time within four weeks prior to the AMB-320/321-E Screening/Randomization Visit.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00578786
Locations
| Argentina | |
| Sanatorio Otamendi | |
| Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1115AAB | |
| Hospital Britanico-Buenos Aires | |
| Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1280AEB | |
| Instituto del Corazon Denton A. Cooley | |
| Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1416A | |
| UAI Hosp. Universitario | |
| Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1437BZL | |
| HIGA Hospital Interzonal General de Agudos Oscar Allende | |
| Mar del Plata, Buenos Aires, Argentina, 07600 | |
| Clinica Independencia Munro | |
| Munro, Buenos Aires, Argentina, 01605 | |
| Hospital Italiano de Rosario | |
| Rosario, Sante Fe, Argentina, 02000 | |
| Sanatorio Allende | |
| Cordoba, Argentina, X5000JHQ | |
| Hospital Italiano de Cordoba | |
| Cordoba, Argentina, X5004 FJE | |
| Hospital Privado Centro Medico de Cordoba | |
| Cordoba, Argentina, X5016KEH | |
| Instituto de Cardiologia J.F. Cabral | |
| Corrientes, Argentina, W3400AMZ | |
| Brazil | |
| Hospital Universitario Clementino Fraga Filho | |
| Ilha do Fundao, Rio de Janeiro, Brazil, 21941-590 | |
| Hospital Madre Teresa | |
| Belo Horizonte, Brazil, 30380-090 | |
| Hospital San Lucas de Pontificia Universidade Catolica | |
| Porto Alegre, Brazil, 90610-000 | |
| Complexo Hospitalar Sanata Casa de Porto Alegre | |
| Porto Alegre, Brazil, 92020-090 | |
| Universidade do Estado de Sao Paulo - UNIFESP | |
| Sao Paulo, Brazil, 04023-062 | |
| Hospital das Clinicas da FMUSP | |
| Sao Paulo, Brazil, 05403-000 | |
| Chile | |
| Hospital San Juan de Dios | |
| Santiago, Santiago de Chile, Chile, CP 8330024 | |
| Hospital Clinico Universidad Catolica | |
| Santiago, Santiago de Chile, Chile, CP 8350488 | |
| Instituto Nacional del Torax | |
| Santiago, Santiago de Chile, Chile, CP7500691 | |
| Mexico | |
| Instituto Nacional de Cardiologia Ignacio Chavez | |
| Mexico, DF, DF, Mexico, 14080 | |
| Unidad De Investigacion Clinica en Medicina | |
| Monterrey, Nuevo Leon, Nuevo Leon, Mexico, 64718 | |
Sponsors and Collaborators
Gilead Sciences
Investigators
| Study Chair: | Chris Dufton, PhD | Gilead Sciences |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Gilead Sciences |
| ClinicalTrials.gov Identifier: | NCT00578786 History of Changes |
| Other Study ID Numbers: |
AMB-320/321-E ARIES-E |
| First Posted: | December 21, 2007 Key Record Dates |
| Results First Posted: | January 15, 2013 |
| Last Update Posted: | January 15, 2013 |
| Last Verified: | January 2013 |
Additional relevant MeSH terms:
|
Familial Primary Pulmonary Hypertension Hypertension Vascular Diseases Cardiovascular Diseases Hypertension, Pulmonary |
Lung Diseases Respiratory Tract Diseases Ambrisentan Antihypertensive Agents |